Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19571794,half-life,"Accordingly, to simulate the pharmacokinetic profile of a human METH binge exposure in rats, we used a computer-controlled, intravenous METH procedure (dynamic infusion, DI) to overcome species differences in METH pharmacokinetics and to replicate the human 12-h plasma METH half-life.",Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19571794/),h,12,6679,DB01577,Methamphetamine
,9210980,clearance,"The clearance of D-OHMAP (93.5 mL min-1 kg-1) was slightly, but statistically significantly, greater than that of the L-enantiomer (83.9 mL min-1 kg-1).",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[ml] / [kg·min],93.5,7220,DB01577,Methamphetamine
,9210980,clearance,"The clearance of D-OHMAP (93.5 mL min-1 kg-1) was slightly, but statistically significantly, greater than that of the L-enantiomer (83.9 mL min-1 kg-1).",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[ml] / [kg·min],83.9,7221,DB01577,Methamphetamine
,9210980,steady-state volumes of distribution,"The steady-state volumes of distribution of L- and D-OHMAP were (mean +/- SD) 3.15 +/- 0.84 and 4.23 +/- 1.76 L kg-1, respectively.",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[l] / [kg],3.15,7222,DB01577,Methamphetamine
,9210980,steady-state volumes of distribution,"The steady-state volumes of distribution of L- and D-OHMAP were (mean +/- SD) 3.15 +/- 0.84 and 4.23 +/- 1.76 L kg-1, respectively.",p-Hydroxymethamphetamine enantiomer pharmacokinetics and metabolism in rats: absence of N-demethylation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210980/),[l] / [kg],4.23,7223,DB01577,Methamphetamine
,10565845,volume of distribution at steady state,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),[l] / [kg],9.0,9699,DB01577,Methamphetamine
,10565845,total clearance,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),[ml] / [kg·min],126,9700,DB01577,Methamphetamine
,10565845,distribution,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),min,9.2,9701,DB01577,Methamphetamine
,10565845,elimination half-lives,"After the 1.0 mg/kg dose, the volume of distribution at steady state was 9.0 liters/kg, the total clearance was 126 ml/min/kg, and the average distribution and elimination half-lives were 9.2 and 63.0 min, respectively.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),min,63.0,9702,DB01577,Methamphetamine
,10565845,T(1/2lambdaz),"(+)-AMP serum concentrations after the 1.0 mg/kg dose peaked from 10 to 30 min, and exhibited a T(1/2lambdaz) of 98.5 min.",Spontaneous locomotor activity and pharmacokinetics of intravenous methamphetamine and its metabolite amphetamine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565845/),min,98.5,9703,DB01577,Methamphetamine
<,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.3,12075,DB01577,Methamphetamine
>,11417445,S/R ratio,Six extensive (mephenytoin S/R ratio < 0.3; EM) and six poor (mephenytoin S/R ratio > 0.8; PM) hydroxylators of S-mephenytoin ingested a single 10-mg oral dose of selegiline hydrochloride.,CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11417445/),,0.8,12076,DB01577,Methamphetamine
,24141857,Cmax,"After 2.5 mg/kg MDMA, mean MDMA Cmax was 164 ± 47.1 ng/ml, HHMA and HMMA were major metabolites, and <20% of MDMA was metabolized to MDA.","Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141857/),[ng] / [ml],164,26137,DB01577,Methamphetamine
,8104133,bioavailability,The bioavailability of smoked methamphetamine was 90.3 +/- 10.4%.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),%,90.3,29520,DB01577,Methamphetamine
,8104133,Oral bioavailability,(Oral bioavailability calculated from this study and a previous one was 67.2 +/- 3.1%).,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),%,67.2,29521,DB01577,Methamphetamine
,8104133,plasma half-life,The geometric mean plasma half-life was 11.1 hr for smoked methamphetamine and 12.2 hr for the intravenous drug.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,11.1,29522,DB01577,Methamphetamine
,8104133,plasma half-life,The geometric mean plasma half-life was 11.1 hr for smoked methamphetamine and 12.2 hr for the intravenous drug.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,12.2,29523,DB01577,Methamphetamine
,8104133,volume of distribution in the elimination phase,The volume of distribution in the elimination phase was 3.24 +/- 0.36 liter/kg for the smoked dose and 3.73 +/- 0.59 liter/kg for the intravenous dose.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),[l] / [kg],3.24,29524,DB01577,Methamphetamine
,8104133,volume of distribution in the elimination phase,The volume of distribution in the elimination phase was 3.24 +/- 0.36 liter/kg for the smoked dose and 3.73 +/- 0.59 liter/kg for the intravenous dose.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),[l] / [kg],3.73,29525,DB01577,Methamphetamine
,8104133,mean residence times,The mean residence times were 11.5 +/- 0.5 hr and 11.3 +/- 1.74 hr for the two routes.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,11.5,29526,DB01577,Methamphetamine
,8104133,mean residence times,The mean residence times were 11.5 +/- 0.5 hr and 11.3 +/- 1.74 hr for the two routes.,Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8104133/),h,11.3,29527,DB01577,Methamphetamine
,14993256,equilibrium dissociation constant (K(d)),"Intravenous administration of a 1 g/kg dose of the lower affinity [antibody equilibrium dissociation constant (K(d)) = 250 nM] monoclonal antibody (mAb) designated mAb6H8, 1 day before the start of several daily 2-h self-administration sessions produced effects that depended on the dose of (+)-methamphetamine.",Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14993256/),nM,250,30452,DB01577,Methamphetamine
,14993256,K(d),"Intravenous administration of a 1 or a 0.6 g/kg dose of a higher affinity (K(d) = 11 nM) mAb designated mAb6H4, 24 h before the first of several self-administration sessions, produced very similar effects to the lower affinity mAb, despite the more than 20-fold greater affinity for (+)-methamphetamine.",Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14993256/),nM,11,30453,DB01577,Methamphetamine
>,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39088,DB01577,Methamphetamine
<,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39089,DB01577,Methamphetamine
,15319342,elimination half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,4.8,39090,DB01577,Methamphetamine
,15319342,half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,14.8,39091,DB01577,Methamphetamine
>,26395866,R/S ratios,"R/S ratios were >1 for all analytes after 24 hours, independent of the initial chiral preference.","Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26395866/),,1,39803,DB01577,Methamphetamine
,14628189,area-under-the curve (AUC(0- infinity)),Mean [SD] area-under-the curve (AUC(0- infinity)) values following Zydis Selegiline 10 mg (5.85 [7.31] ng.h/mL) were approximately five times higher than those following conventional selegiline tablets 10 mg (1.16 [1.05] ng.h/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[h·ng] / [ml],5.85,41070,DB01577,Methamphetamine
,14628189,area-under-the curve (AUC(0- infinity)),Mean [SD] area-under-the curve (AUC(0- infinity)) values following Zydis Selegiline 10 mg (5.85 [7.31] ng.h/mL) were approximately five times higher than those following conventional selegiline tablets 10 mg (1.16 [1.05] ng.h/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[h·ng] / [ml],1.16,41071,DB01577,Methamphetamine
,14628189,C(max),The C(max) of selegiline was similar following administration of Zydis Selegiline 1.25 mg (1.52 ng/mL) or conventional selegiline tablets 10 mg (1.14 mg/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],1.52,41072,DB01577,Methamphetamine
,14628189,C(max),The C(max) of selegiline was similar following administration of Zydis Selegiline 1.25 mg (1.52 ng/mL) or conventional selegiline tablets 10 mg (1.14 mg/mL).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[mg] / [ml],1.14,41073,DB01577,Methamphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],1.19,41074,DB01577,Methamphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],0.34,41075,DB01577,Methamphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],0.93,41076,DB01577,Methamphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],18.37,41077,DB01577,Methamphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],3.60,41078,DB01577,Methamphetamine
,14628189,peak plasma concentrations,"As expected, peak plasma concentrations for DMS, AMT and MET were consistently lower after Zydis Selegiline 1.25 mg (1.19, 0.34, 0.93 ng/ml, respectively) than after conventional selegiline tablets 10 mg (18.37, 3.60, 12.92 ng/ml, respectively).",A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),[ng] / [ml],12.92,41079,DB01577,Methamphetamine
,14628189,excretion,Mean daily PEA excretion was similar following Zydis Selegiline 1.25 mg and conventional selegiline tablets 10 mg (13.0 microg versus 17.6 microg).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),μg,13.0,41080,DB01577,Methamphetamine
,14628189,excretion,Mean daily PEA excretion was similar following Zydis Selegiline 1.25 mg and conventional selegiline tablets 10 mg (13.0 microg versus 17.6 microg).,A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14628189/),μg,17.6,41081,DB01577,Methamphetamine
,3984382,biological half-life of the alpha phase (t alpha 1/2),"The biological half-life of the alpha phase (t alpha 1/2) was 6.8 +/- 2.0 min, and that of the beta phase (t beta 1/2) was 11.3 +/- 0.8 h.","Distribution and excretion of methamphetamine and its metabolites in rats. Time-course of concentrations in blood and bile, and distribution after intravenous administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3984382/),min,6.8,42756,DB01577,Methamphetamine
,3984382,t beta 1/2),"The biological half-life of the alpha phase (t alpha 1/2) was 6.8 +/- 2.0 min, and that of the beta phase (t beta 1/2) was 11.3 +/- 0.8 h.","Distribution and excretion of methamphetamine and its metabolites in rats. Time-course of concentrations in blood and bile, and distribution after intravenous administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3984382/),h,11.3,42757,DB01577,Methamphetamine
,18455783,time to maximum concentration,The time to maximum concentration for METH and AMP following i.m. administration was 0.3 h.,Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18455783/),h,0.3,43633,DB01577,Methamphetamine
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],1.0,44209,DB01577,Methamphetamine
,18089653,Limits of quantification,"Limits of quantification were 1.0 microg/L for MDA and 2.5 microg/L for MDEA, MDMA, HMMA, and HMA.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),[μg] / [l],2.5,44210,DB01577,Methamphetamine
> or =,18089653,overall extraction efficiencies,"At 3 concentrations spanning the linear dynamic range of the assay, mean overall extraction efficiencies from plasma were > or =85% for all compounds of interest.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85,44211,DB01577,Methamphetamine
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,85.6,44212,DB01577,Methamphetamine
,18089653,Recoveries,"Recoveries were 85.6% to 107.2% of target, and intra- and interassay imprecision (CV) was <8.5% for all drugs at 3 concentrations within the range of the assay.","Two-dimensional gas chromatography/electron-impact mass spectrometry with cryofocusing for simultaneous quantification of MDMA, MDA, HMMA, HMA, and MDEA in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18089653/),%,107.2,44213,DB01577,Methamphetamine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,2.58,44913,DB01577,Methamphetamine
,20815935,cross-membrane permeability (Pm*),The cross-membrane permeability (Pm*) determined in rat jejunal perfusion of D-phenylglycine-L-dopa was higher than that of L-dopa (2.58 ± 0.14 vs. 0.94 ± 0.10).,Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20815935/),,0.94,44914,DB01577,Methamphetamine
,31058136,Extra,"Extraction recoveries ranged from 48.6 to 105.4% with coefficients of variation (CV) ≤ 13.7%, and matrix effects ranged from 45.4 to 104.1% with CV ≤ 10.3%.","Simultaneous Determination of Selegiline, Desmethylselegiline, R/S-methamphetamine, and R/S-amphetamine on Dried Urine Spots by LC/MS/MS: Application to a Pharmacokinetic Study in Urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31058136/),%,48.6 to 105.4,52709,DB01577,Methamphetamine
,22832282,T(max),A pharmacokinetic study found a T(max) of 0.25 h and a C(max) of 1206 ng/ml after 5.6 mg/kg 4-MMC.,"Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832282/),h,0.25,65214,DB01577,Methamphetamine
,22832282,C(max),A pharmacokinetic study found a T(max) of 0.25 h and a C(max) of 1206 ng/ml after 5.6 mg/kg 4-MMC.,"Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22832282/),[ng] / [ml],1206,65215,DB01577,Methamphetamine
,20962030,terminal elimination half-life (t(1/2λz)),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,6.6,65669,DB01577,Methamphetamine
,20962030,t(1/2λz),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,3.7,65670,DB01577,Methamphetamine
,20962030,t(1/2λz),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,1.4,65671,DB01577,Methamphetamine
,20962030,t(1/2λz),"Whereas anti-PCP mAb6B5 terminal elimination half-life (t(1/2λz)) in nonpregnant females was 6.6 ± 1.6 days, the mAb6B5 t(1/2λz) significantly changed to 3.7 ± 0.4 days, then 1.4 ± 0.1 days, then 3.0 ± 0.4 days in the second trimester, third trimester, and postpartum periods, respectively (p < 0.05 for each change).",The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962030/),d,3.0,65672,DB01577,Methamphetamine
,24884590,pEC50,3-[2-(3-Chloro-5-fluorobenzyl)-1-benzothiophen-7-yl]-N-(2-methoxyethyl)benzamide 7m showed potent activity (pEC50 = 7.53 ± 0.08) and good pharmacokinetic properties.,Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24884590/),,7.53,70033,DB01577,Methamphetamine
,23545806,"V(max,1)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),[nM] / [mg·min],0.046,72744,DB01577,Methamphetamine
,23545806,"K(m,1)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),μM,19.0,72745,DB01577,Methamphetamine
,23545806,"V(max,2)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),[nM] / [mg·min],0.22,72746,DB01577,Methamphetamine
,23545806,"K(m,2)","Measuring the formation of the major metabolite, biphasic Michaelis-Menten kinetic parameters were determined: V(max,1) = 0.046 ± 0.005 (S.E.) nmol/min/mg protein, K(m,1) = 19.0 ± 4.2 μM, V(max,2) = 0.22 ± 0.04 nmol/min/mg protein, and K(m,2) = 1953 ± 761 μM; the low-capacity and high-affinity contribution was assigned to the activity of CYP2D6.",In vitro metabolism and pharmacokinetic studies on methylone. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),μM,1953,72747,DB01577,Methamphetamine
,23545806,K(I),The inactivation parameters were determined to be K(I) = 15.1 ± 3.4 (S.E.) μM and k(inact) = 0.075 ± 0.005 minute(-1).,In vitro metabolism and pharmacokinetic studies on methylone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),μM,15.1,72748,DB01577,Methamphetamine
,23545806,k(inact),The inactivation parameters were determined to be K(I) = 15.1 ± 3.4 (S.E.) μM and k(inact) = 0.075 ± 0.005 minute(-1).,In vitro metabolism and pharmacokinetic studies on methylone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23545806/),1/[minute],0.075,72749,DB01577,Methamphetamine
,12586207,K(d),Our studies examined pharmacokinetic mechanisms involved in high-affinity (K(d) approximately 11 nM) monoclonal antibody-based antagonism of (+)-methamphetamine-induced locomotor effects.,Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12586207/),nM,11,75019,DB01577,Methamphetamine
,12507968,c(max),"After the first oral dose, initial plasma METH detection was within 0.25-2 h; c(max) was 14.5-33.8 micro g/L (10 mg) and 26.2-44.3 micro g/L (20 mg) within 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],14.5-33.8,76508,DB01577,Methamphetamine
,12507968,c(max),"After the first oral dose, initial plasma METH detection was within 0.25-2 h; c(max) was 14.5-33.8 micro g/L (10 mg) and 26.2-44.3 micro g/L (20 mg) within 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],26.2-44.3,76509,DB01577,Methamphetamine
,12507968,c(max),"In oral fluid, METH was detected as early as 0.08-2 h; c(max) was 24.7-312.2 micro g/L (10 mg) and 75.3-321.7 micro g/L (20 mg) and occurred at 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],24.7-312.2,76510,DB01577,Methamphetamine
,12507968,c(max),"In oral fluid, METH was detected as early as 0.08-2 h; c(max) was 24.7-312.2 micro g/L (10 mg) and 75.3-321.7 micro g/L (20 mg) and occurred at 2-12 h.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],75.3-321.7,76511,DB01577,Methamphetamine
,12507968,oral fluid-plasma METH,The median oral fluid-plasma METH concentration ratio was 2.0 across 24 h and was highly variable.,Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),,2.0,76512,DB01577,Methamphetamine
,12507968,concentration ratio,The median oral fluid-plasma METH concentration ratio was 2.0 across 24 h and was highly variable.,Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),,2.0,76513,DB01577,Methamphetamine
,12507968,areas under the curve,"Mean (SD) areas under the curve for AMP were 21% +/- 25% and 24% +/- 11% of those observed for METH in plasma and oral fluid, respectively.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),,21,76514,DB01577,Methamphetamine
,12507968,areas under the curve,"Mean (SD) areas under the curve for AMP were 21% +/- 25% and 24% +/- 11% of those observed for METH in plasma and oral fluid, respectively.",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),%,24,76515,DB01577,Methamphetamine
,12507968,detection window,"After a single low or high dose, plasma METH was >2.5 micro g/L for up to 24 h in 9 of 12 individuals (mean, 7.3 +/- 5.5 micro g/L at 24 h); in oral fluid the detection window was at least 24 h (mean, 18.8 +/- 18.0 micro g/L at 24 h).",Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12507968/),[μg] / [l],18.8,76516,DB01577,Methamphetamine
,23603357,α,The plasma concentrations after i.v. administration were described by a two-compartment model with distribution and terminal elimination phases of α=1.95 h(-1) and β=0.72 h(-1).,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),1/[h],1.95,81812,DB01577,Methamphetamine
,23603357,β,The plasma concentrations after i.v. administration were described by a two-compartment model with distribution and terminal elimination phases of α=1.95 h(-1) and β=0.72 h(-1).,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),1/[h],0.72,81813,DB01577,Methamphetamine
,23603357,Absolute bioavailability,Absolute bioavailability was about 80% and the percentage of methylone protein binding was of 30%.,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),%,80,81814,DB01577,Methamphetamine
,23603357,percentage of,Absolute bioavailability was about 80% and the percentage of methylone protein binding was of 30%.,"An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methylone, a synthetic cathinone sold as ""bath salts"". ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23603357/),%,30,81815,DB01577,Methamphetamine
,9797797,Peak serum concentrations,Peak serum concentrations of selegiline were reached rapidly and ranged from 1 to 32 nmol/L.,CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[nM] / [l],1 to 32,84693,DB01577,Methamphetamine
,9797797,50% inhibitory concentration,"The inhibitory potency of selegiline, desmethylselegiline, and l-methamphetamine toward dextromethorphan O-demethylase was very low (50% inhibitory concentration values from 160 to 580 mumol/L).",CYP2D6 polymorphism is not crucial for the disposition of selegiline. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9797797/),[μM] / [l],160 to 580,84694,DB01577,Methamphetamine
,27474358,limits of detection,"These conditions allowed for limits of detection of 1ng/mL for MDPV, and 5 ng/mL for both mephedrone and methylone.",Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474358/),[ng] / [ml],1,87074,DB01577,Methamphetamine
,27474358,limits of detection,"These conditions allowed for limits of detection of 1ng/mL for MDPV, and 5 ng/mL for both mephedrone and methylone.",Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474358/),[ng] / [ml],5,87075,DB01577,Methamphetamine
,18192498,K(d),"With medical treatment as a goal, a novel single-chain variable fragment (scFv) against METH was engineered from anti-METH monoclonal antibody mAb6H4 (IgG, kappa light chain, K(d) = 11 nM) and found to have similar ligand affinity (K(d) = 10 nM) and specificity as mAb6H4.",Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),nM,11,87800,DB01577,Methamphetamine
,18192498,K(d),"With medical treatment as a goal, a novel single-chain variable fragment (scFv) against METH was engineered from anti-METH monoclonal antibody mAb6H4 (IgG, kappa light chain, K(d) = 11 nM) and found to have similar ligand affinity (K(d) = 10 nM) and specificity as mAb6H4.",Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),nM,10,87801,DB01577,Methamphetamine
,18192498,apparent t(1/2lambdaz),The scFv6H4 monomer was quickly cleared or converted to multivalent forms with an apparent t(1/2lambdaz) of 5.8 min.,Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),min,5.8,87802,DB01577,Methamphetamine
,18192498,t(1/2lambdaz),"In contrast, the larger scFv6H4 multivalent forms (dimers, trimers, etc.) showed a much longer t(1/2lambdaz) (228 min), and the significantly increased METH serum molar concentrations correlated directly with scFv6H4 serum molar concentrations.",Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192498/),min,228,87803,DB01577,Methamphetamine
,17625500,peak plasma METH concentrations,"METH doses were escalated over 33 weeks, with final dosages resulting in estimated peak plasma METH concentrations of 1-3 microM, a range measured in human abusers.",Long-term methamphetamine administration in the vervet monkey models aspects of a human exposure: brain neurotoxicity and behavioral profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625500/),μM,1-3,88339,DB01577,Methamphetamine
,30614204,initial detection time,"After oral administration, each analyte could be detected in OF specimens from all volunteers with an initial detection time of 0.50 hours.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,0.50,89117,DB01577,Methamphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],50.93-992.67,89118,DB01577,Methamphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],29.78-653.64,89119,DB01577,Methamphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],8.22-150.15,89120,DB01577,Methamphetamine
,30614204,Cmax,"The Cmax values of SG, R-MA, R-AM and DM-SG were 50.93-992.67 ng/mL, 29.78-653.64 ng/mL, 8.22-150.15 ng/mL, and 4.34-16.25 ng/mL, respectively, at 0.5 hours, 1-11 hours, 1.5-11 hours, and 0.5-6 hours post dose.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),[ng] / [ml],4.34-16.25,89121,DB01577,Methamphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,5-24,89122,DB01577,Methamphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,52-96,89123,DB01577,Methamphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,31-96,89124,DB01577,Methamphetamine
,30614204,times,"The times when the compounds were last determined in OF were 5-24 hours for SG, 52-96 hours for R-MA, 31-96 hours for R-AM, and 13-31 hours for DM-SG after oral administration.","Pharmacokinetics of selegiline, R-methamphetamine, R-amphetamine, and desmethylselegiline in oral fluid after a single oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30614204/),h,13-31,89125,DB01577,Methamphetamine
,15570192,Maximum excretion rates,Maximum excretion rates ranged from 403 to 4919 microg/h for methamphetamine and 59 to 735 microg/h for amphetamine with no relationship between dose and excretion rate.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),[μg] / [h],403 to 4919,92827,DB01577,Methamphetamine
,15570192,Maximum excretion rates,Maximum excretion rates ranged from 403 to 4919 microg/h for methamphetamine and 59 to 735 microg/h for amphetamine with no relationship between dose and excretion rate.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),[μg] / [h],59 to 735,92828,DB01577,Methamphetamine
,15570192,molar percentage of dose,The mean molar percentage of dose in the urine as total methamphetamine and amphetamine were 57.5 +/- 21.7% (low dose) and 40.9 +/- 8.5% (high dose).,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),%,57.5,92829,DB01577,Methamphetamine
,15570192,molar percentage of dose,The mean molar percentage of dose in the urine as total methamphetamine and amphetamine were 57.5 +/- 21.7% (low dose) and 40.9 +/- 8.5% (high dose).,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),%,40.9,92830,DB01577,Methamphetamine
,15570192,urinary terminal elimination half-lives,Mean urinary terminal elimination half-lives across doses were 23.6 +/- 6.6 hours for methamphetamine and 20.7 +/- 7.3 hours for amphetamine.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),h,23.6,92831,DB01577,Methamphetamine
,15570192,urinary terminal elimination half-lives,Mean urinary terminal elimination half-lives across doses were 23.6 +/- 6.6 hours for methamphetamine and 20.7 +/- 7.3 hours for amphetamine.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),h,20.7,92832,DB01577,Methamphetamine
,15570192,renal clearance,Methamphetamine renal clearance across doses was 175 +/- 102 mL/min.,"Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570192/),[ml] / [min],175,92833,DB01577,Methamphetamine
,21151866,clearance,"Methamphetamine's clearance was fastest in heart and lungs (7-16 minutes), slowest in brain, liver and stomach (>75 minutes), and intermediate in kidneys, spleen and pancreas (22-50 minutes).",Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21151866/),min,7-16,97494,DB01577,Methamphetamine
>,21151866,clearance,"Methamphetamine's clearance was fastest in heart and lungs (7-16 minutes), slowest in brain, liver and stomach (>75 minutes), and intermediate in kidneys, spleen and pancreas (22-50 minutes).",Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21151866/),min,75,97495,DB01577,Methamphetamine
,21151866,clearance,"Methamphetamine's clearance was fastest in heart and lungs (7-16 minutes), slowest in brain, liver and stomach (>75 minutes), and intermediate in kidneys, spleen and pancreas (22-50 minutes).",Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21151866/),min,22-50,97496,DB01577,Methamphetamine
,29971461,Cmax,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l],16.4,104026,DB01577,Methamphetamine
,29971461,Cmax,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l],62.2,104027,DB01577,Methamphetamine
,29971461,AUC0 → ∞,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l·min],708,104028,DB01577,Methamphetamine
,29971461,AUC0 → ∞,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μg] / [l·min],3316,104029,DB01577,Methamphetamine
,29971461,V/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg],582.6,104030,DB01577,Methamphetamine
,29971461,V/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg],115.9,104031,DB01577,Methamphetamine
,29971461,Cl/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg·min],4.6,104032,DB01577,Methamphetamine
,29971461,Cl/F,"The pharmacokinetic profile of MDPV, but not 4-MMC, was significantly modified with the combination resulting in decreases in Cmax (16.4 ± 5.5 versus 62.2 ± 14.2 μg/L, p < 0.05) and AUC0 → ∞ (708 ± 91 versus 3316 ± 682 μg/L/min, p < 0.01) and increases in V/F (582.6 ± 136.8 versus 115.9 ± 42.7 L/kg, p < 0.05) and Cl/F (4.6 ± 0.7 versus 1.2 ± 0.4 L/kg/min, p < 0.01) in comparison to MDPV alone.","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[l] / [kg·min],1.2,104033,DB01577,Methamphetamine
,29971461,EC50,"The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L).","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μM] / [l],0.043,104034,DB01577,Methamphetamine
,29971461,EC50,"The sigmoidal Emax model fitted the observed data well; MDPV being markedly more potent than 4-MMC (EC50, 0.043 versus 0.7 μmol/L).","Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29971461/),[μM] / [l],0.7,104035,DB01577,Methamphetamine
,23649883,α,"Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)).",Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),1/[h],10.23,106059,DB01577,Methamphetamine
,23649883,β,"Mephedrone plasma concentrations after i.v. administration fit a two-compartment model (α = 10.23 h(-1), β = 1.86 h(-1)).",Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),1/[h],1.86,106060,DB01577,Methamphetamine
,23649883,absolute bioavailability,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,10,106061,DB01577,Methamphetamine
,23649883,percentage of,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,21.59,106062,DB01577,Methamphetamine
,23649883,protein binding,The absolute bioavailability of mephedrone was about 10% and the percentage of mephedrone protein binding was 21.59 ± 3.67%.,Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23649883/),%,21.59,106063,DB01577,Methamphetamine
,17015058,elimination half-lives,The elimination half-lives were longer for l-methamphetamine (13.3-15.0 hours) than for d-methamphetamine (10.2-10.7 hours) (P < .0001).,Human pharmacology of the methamphetamine stereoisomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),h,13.3-15.0,107796,DB01577,Methamphetamine
,17015058,elimination half-lives,The elimination half-lives were longer for l-methamphetamine (13.3-15.0 hours) than for d-methamphetamine (10.2-10.7 hours) (P < .0001).,Human pharmacology of the methamphetamine stereoisomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),h,10.2-10.7,107797,DB01577,Methamphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],18.7,107798,DB01577,Methamphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],13.5,107799,DB01577,Methamphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],10.7,107800,DB01577,Methamphetamine
,17015058,peak heart rate changes,"The peak heart rate changes after racemic methamphetamine and 0.5 mg/kg d- and l-methamphetamine were similar (18.7 +/- 23.4 beats/min, 13.5 +/- 18.5 beats/min, and 10.7 +/- 10.2 beats/min, respectively), but racemic methamphetamine and 0.5 mg/kg d-methamphetamine increased systolic blood pressure more than 0.5 mg/kg l-methamphetamine (33.4 +/- 17.8 beats/min and 34.5 +/- 18.9 beats/min, respectively, versus 19.5 +/- 11.3 beats/min; P < .01).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),[beats] / [min],19,107801,DB01577,Methamphetamine
,17015058,peak intoxication,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,46,107802,DB01577,Methamphetamine
,17015058,peak intoxication,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,30.3,107803,DB01577,Methamphetamine
,17015058,drug,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,47.7,107804,DB01577,Methamphetamine
,17015058,drug,"l-Methamphetamine, 0.5 mg/kg, was psychoactive, producing peak intoxication (46.0 +/- 35.3 versus 30.3 +/- 24.9) and drug liking (47.7 +/- 35.1 versus 28.6 +/- 24.8) ratings similar to 0.5 mg/kg d-methamphetamine, but the effects of l-methamphetamine dissipated more quickly (approximately 3 hours versus 6 hours).",Human pharmacology of the methamphetamine stereoisomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17015058/),,28.6,107805,DB01577,Methamphetamine
,14570763,KD,These studies examined the effects of a high-affinity anti-(+)-methamphetamine monoclonal antibody (mAb; KD = 11 nM) on (+)-methamphetamine [(+)-METH] and (+)-amphetamine [(+)-AMP] serum and tissue disposition and serum protein binding following i.v. (+)-METH administration.,Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570763/),nM,11,114263,DB01577,Methamphetamine
,7995016,half-life of recovery,"In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days.",Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995016/),d,8 to 12,114602,DB01577,Methamphetamine
,7995016,half-life of recovery,"In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days.",Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995016/),d,1 to 3,114603,DB01577,Methamphetamine
,27658484,Tmax,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,15-45,119370,DB01577,Methamphetamine
,27658484,t1/2,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,60-90,119371,DB01577,Methamphetamine
,27658484,Tmax,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,60-120,119372,DB01577,Methamphetamine
,27658484,t1/2,"For the PK study, we found that methylone and MDC peaked early (Tmax=15-45 min) and were short lived (t1/2=60-90 min), while HHMC and HMMC peaked later (Tmax=60-120 min) and persisted (t1/2=120-180 min).",Pharmacokinetic Profiles and Pharmacodynamic Effects for Methylone and Its Metabolites in Rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658484/),min,120-180,119373,DB01577,Methamphetamine
>,11862224,first-pass extraction,"The transdermal administration of SEL bypasses the first-pass metabolism, that is significant after oral administration (first-pass extraction >90%).",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),%,90,125181,DB01577,Methamphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],1.19,125182,DB01577,Methamphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],23.22,125183,DB01577,Methamphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],4.78,125184,DB01577,Methamphetamine
,11862224,Peak plasma levels,"Peak plasma levels of 1.19, 23.22, 4.78, and 14.08 ng/mL were observed for SEL, DMS, AMP, and MET after a single 10-mg oral dose to the elderly.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],14.08,125185,DB01577,Methamphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],2.10,125186,DB01577,Methamphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],0.85,125187,DB01577,Methamphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],1.06,125188,DB01577,Methamphetamine
,11862224,peak plasma levels,"By contrast, peak plasma levels of 2.10, 0.85, 1.06, and 2.71 ng/mL were observed for SEL, DMS, AMP, and MET after a single 24-h application of 1 STS.",Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862224/),[ng] / [ml],2.71,125189,DB01577,Methamphetamine
,32986113,Tmax,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),min,52.5,125557,DB01577,Methamphetamine
,32986113,Tmax,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),min,55.0,125558,DB01577,Methamphetamine
,32986113,t1/2,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),h,1.98,125559,DB01577,Methamphetamine
,32986113,t1/2,"Compared to other psychostimulants, mephedrone showed rapid absorption (mean Tmax of 52.5 ± 20.7 min in plasma and 55.0 ± 18.2 min in whole blood) and elimination (mean t1/2 of 1.98 ± 0.30 h in plasma and 2.12 ± 0.33 h in whole blood).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),h,2.12,125560,DB01577,Methamphetamine
,32986113,whole blood to plasma distribution ratios,"In addition, statistical analysis showed that median whole blood to plasma distribution ratios, reported here for the first time, were statistically different from 1 (unity) for mephedrone (median: 1.11), DHM (median: 1.30) and NOR (median: 0.765).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),,1,125561,DB01577,Methamphetamine
,32986113,whole blood to plasma distribution ratios,"In addition, statistical analysis showed that median whole blood to plasma distribution ratios, reported here for the first time, were statistically different from 1 (unity) for mephedrone (median: 1.11), DHM (median: 1.30) and NOR (median: 0.765).",Pharmacokinetics of Mephedrone and Its Metabolites in Whole Blood and Plasma after Controlled Intranasal Administration to Healthy Human Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32986113/),,0,125562,DB01577,Methamphetamine
,6628439,half-life,When the mouse was pretreated with a MAO inhibitor (pargyline hydrochloride 100 mg/kg IP) the radioactivity was rapidly excreted from the brain with a half-life of about 45 min.,A new metabolically trapped agent by brain monoamine oxidase: N-methyl labeled (14C) N-methylphenylethylamine (14C-MPEA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628439/),min,45,125694,DB01577,Methamphetamine
,22815533,K(i),"ABT-288 is a competitive antagonist with high affinity and selectivity for human and rat H(3)Rs (K(i) = 1.9 and 8.2 nM, respectively) that enhances the release of acetylcholine and dopamine in rat prefrontal cortex.","Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22815533/),nM,1.9,140018,DB01577,Methamphetamine
,22815533,K(i),"ABT-288 is a competitive antagonist with high affinity and selectivity for human and rat H(3)Rs (K(i) = 1.9 and 8.2 nM, respectively) that enhances the release of acetylcholine and dopamine in rat prefrontal cortex.","Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22815533/),nM,8.2,140019,DB01577,Methamphetamine
,22815533,oral bioavailability,"ABT-288 demonstrated a number of other favorable attributes, including good pharmacokinetics and oral bioavailability of 37 to 66%, with a wide central nervous system and cardiovascular safety margin.","Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22815533/),%,37 to 66,140020,DB01577,Methamphetamine
,26452730,half-life,The half-life values for MA in the breast milk were 11.3 and 40.3 hours.,Transfer of Methamphetamine (MA) into Breast Milk and Urine of Postpartum Women who Smoked MA Tablets during Pregnancy: Implications for Initiation of Breastfeeding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452730/),h,11.3,140725,DB01577,Methamphetamine
,26452730,half-life,The half-life values for MA in the breast milk were 11.3 and 40.3 hours.,Transfer of Methamphetamine (MA) into Breast Milk and Urine of Postpartum Women who Smoked MA Tablets during Pregnancy: Implications for Initiation of Breastfeeding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452730/),h,40.3,140726,DB01577,Methamphetamine
,25484042,half-life,"Ch-mAb7F9 displayed expected IgG pharmacokinetic parameters, including a half-life of 17-19 d in the 3 highest dose groups and volume of distribution of 5-6 L, suggesting the antibody is confined primarily to the vascular compartment.",First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484042/),d,17-19,141875,DB01577,Methamphetamine
,25484042,volume of distribution,"Ch-mAb7F9 displayed expected IgG pharmacokinetic parameters, including a half-life of 17-19 d in the 3 highest dose groups and volume of distribution of 5-6 L, suggesting the antibody is confined primarily to the vascular compartment.",First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25484042/),l,5-6,141876,DB01577,Methamphetamine
,10682227,half-lives,"However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short.",Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682227/),h,1.5-3.5,143558,DB01577,Methamphetamine
,10682227,half-lives,"However, the half-lives of selegiline (range, 1.5-3.5 h) and desmethylselegiline (range, 3.4-5.3 h) were found to be relatively short.",Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10682227/),h,3.4-5.3,143559,DB01577,Methamphetamine
,25804420,plasma half-life,3-MMC displayed rapid absorption with a peak concentration achieved within 5-10 min after oral ingestion and a plasma half-life of 0.8 h.,3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804420/),h,0.8,146241,DB01577,Methamphetamine
,25804420,bioavailability,The bioavailability was about 7%.,3-Methyl-methcathinone: Pharmacokinetic profile evaluation in pigs in relation to pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25804420/),%,7,146242,DB01577,Methamphetamine
,17127110,CL(int),"For PMMA, the SS experiment resulted in a CL(int) of 2.7+/-0.2 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 3.0+/-0.6 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],2.7,146251,DB01577,Methamphetamine
,17127110,CL(int),"For PMMA, the SS experiment resulted in a CL(int) of 2.7+/-0.2 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 3.0+/-0.6 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],3.0,146252,DB01577,Methamphetamine
,17127110,CL(int),"For fluoxetine, the SS experiment resulted in a CL(int) of 0.33+/-0.17 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 0.188+/-0.013 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],0.33,146253,DB01577,Methamphetamine
,17127110,CL(int),"For fluoxetine, the SS experiment resulted in a CL(int) of 0.33+/-0.17 microL pmol 2D6(-1)min(-1) and the GE experiment resulted in a CL(int) of 0.188+/-0.013 microL pmol 2D6(-1)min(-1).",Development of an in vitro incubation procedure for screening of CYP2D6 intrinsic clearance. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17127110/),[pM·μl] / [2d6],0.188,146254,DB01577,Methamphetamine
< or =,17982891,t1/2beta,The peak concentrations (C(max)) were reached at 15 min after treatment and the absorption was followed by a fast elimination (t1/2beta < or = 2h).,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),h,2,146749,DB01577,Methamphetamine
,17982891,bioavailability,Increased bioavailability was detected after subcutaneous (87.1%) and intraperitoneal (78.7%) administration.,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),%,87.1,146750,DB01577,Methamphetamine
,17982891,bioavailability,Increased bioavailability was detected after subcutaneous (87.1%) and intraperitoneal (78.7%) administration.,Pharmacokinetic studies of (-)-deprenyl and some of its metabolites in mouse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17982891/),%,78.7,146751,DB01577,Methamphetamine
,28433511,half maximal effective concentration (EC50),"During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)=75nM, maximal response (Emax)=122%) starting from a high-throughput screening hit 3 (EC50=470nM, Emax=56%).","Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28433511/),nM,75,150540,DB01577,Methamphetamine
,28433511,maximal response (Emax),"During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)=75nM, maximal response (Emax)=122%) starting from a high-throughput screening hit 3 (EC50=470nM, Emax=56%).","Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28433511/),%,122,150541,DB01577,Methamphetamine
,28433511,EC50,"During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)=75nM, maximal response (Emax)=122%) starting from a high-throughput screening hit 3 (EC50=470nM, Emax=56%).","Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28433511/),nM,470,150542,DB01577,Methamphetamine
,28433511,Emax,"During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)=75nM, maximal response (Emax)=122%) starting from a high-throughput screening hit 3 (EC50=470nM, Emax=56%).","Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28433511/),%,56,150543,DB01577,Methamphetamine
,28433511,F,"A structure-activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole derivative 4u, which demonstrated excellent bioavailability in rats (F=53.8%).","Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28433511/),%,53.8,150544,DB01577,Methamphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,79,151609,DB01577,Methamphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,67,151610,DB01577,Methamphetamine
,14586388,bioavailabilities,"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37.4% of the absolute (pipe) dose after smoking.",The bioavailability of intranasal and smoked methamphetamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),%,37.4,151611,DB01577,Methamphetamine
,14586388,elimination half-life,"The elimination half-life was similar for intravenous (11.4 hours), intranasal (10.7 hours), and smoked (10.7 hours) methamphetamine.",The bioavailability of intranasal and smoked methamphetamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,11.4,151612,DB01577,Methamphetamine
,14586388,elimination half-life,"The elimination half-life was similar for intravenous (11.4 hours), intranasal (10.7 hours), and smoked (10.7 hours) methamphetamine.",The bioavailability of intranasal and smoked methamphetamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,10.7,151613,DB01577,Methamphetamine
,14586388,Clearance,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],272,151614,DB01577,Methamphetamine
,14586388,steady-state volume of distribution,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[l] / [kg],4.2,151615,DB01577,Methamphetamine
,14586388,mean residence time,"Clearance (272 mL x h(-1) x kg(-1)), steady-state volume of distribution (4.2 L/kg), and mean residence time (16 hours) of the intravenous dose were similar to previously reported values.",The bioavailability of intranasal and smoked methamphetamine. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,16,151616,DB01577,Methamphetamine
,14586388,half-life,"Dextroamphetamine (INN, dexamfetamine) half-life (all routes) was 16.2 hours.",The bioavailability of intranasal and smoked methamphetamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),h,16.2,151617,DB01577,Methamphetamine
,14586388,renal clearances,"Methamphetamine and dextroamphetamine renal clearances (all routes) were about 100 and 1100 mL x h(-1) x kg(-1), respectively.",The bioavailability of intranasal and smoked methamphetamine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],100,151618,DB01577,Methamphetamine
,14586388,renal clearances,"Methamphetamine and dextroamphetamine renal clearances (all routes) were about 100 and 1100 mL x h(-1) x kg(-1), respectively.",The bioavailability of intranasal and smoked methamphetamine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586388/),[ml] / [h·kg],1100,151619,DB01577,Methamphetamine
,10688621,terminal elimination half-life,"Based on data from the area under the concentration-time curves after i.v. dosing, the rank order of (+)-METH tissue accumulation was kidney > spleen > brain > liver > heart > serum with terminal elimination half-life values ranging from 53 to 66 min.",Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),min,53 to 66,152475,DB01577,Methamphetamine
,10688621,brain-to-serum concentration ratio,The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),,7:1,152476,DB01577,Methamphetamine
,10688621,brain-to-serum concentration ratio,The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),,13:1,152477,DB01577,Methamphetamine
,10688621,brain-to-serum concentration ratio,The brain-to-serum concentration ratio rose from 7:1 at 2 min to a peak of 13:1 at 20 min before equilibrating to a constant value of 8:1 at 2 h.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),,8,152478,DB01577,Methamphetamine
,10688621,terminal elimination half-life,(+)-AMP concentrations peaked at 20 min in all tissues before decaying with terminal elimination half-life values ranging from 68 to 75 min.,Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688621/),min,68 to 75,152479,DB01577,Methamphetamine
>,11916012,peak resolution,Each enantiomer of MBDB and BDB was monitored (peak resolution > 1.00) by HPLC analysis within 30 min.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),,1.00,156420,DB01577,Methamphetamine
,11916012,urinary excretion,The urinary excretion of MBDB showed significant difference between the two enantiomers from 4 to 20 h (p < 0.05).,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),h,4,156421,DB01577,Methamphetamine
,11916012,amount,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,34,156422,DB01577,Methamphetamine
,11916012,amount,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.6,156423,DB01577,Methamphetamine
,11916012,amount,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.1,156424,DB01577,Methamphetamine
,11916012,excreted,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,34,156425,DB01577,Methamphetamine
,11916012,excreted,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.6,156426,DB01577,Methamphetamine
,11916012,excreted,The amount of MBDB excreted up to 24 h was 34.7+/-2.8% of the administered dose: 17.6+/-1.4% for (+)-isomer and 17.1+/-1.5% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,17.1,156427,DB01577,Methamphetamine
,11916012,amount,The amount of BDB was 4.9+/-1.0%; 2.9+/-0.6% for (+)-isomer and 2.0+/-0.4% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),,4,156428,DB01577,Methamphetamine
,11916012,amount,The amount of BDB was 4.9+/-1.0%; 2.9+/-0.6% for (+)-isomer and 2.0+/-0.4% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,2.9,156429,DB01577,Methamphetamine
,11916012,amount,The amount of BDB was 4.9+/-1.0%; 2.9+/-0.6% for (+)-isomer and 2.0+/-0.4% for (-)-isomer.,"Enantiomer analysis of a new street drug, 3,4-methylenedioxy-N-methyl-butanamine, in rat urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11916012/),%,2.0,156430,DB01577,Methamphetamine
,20233182,excretion,"Correspondingly, S-(+)-MA excretion was less than R-(-)-MA (42% vs. 52%; P= 0.005).",Stereoselectivity in the human metabolism of methamphetamine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233182/),%,42,163689,DB01577,Methamphetamine
,20233182,excretion,"Correspondingly, S-(+)-MA excretion was less than R-(-)-MA (42% vs. 52%; P= 0.005).",Stereoselectivity in the human metabolism of methamphetamine. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233182/),%,52,163690,DB01577,Methamphetamine
,26159352,KD,We found that the high affinity (KD = 6.2 nM) and specificity for METH was unchanged after nanoparticle conjugation.,A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26159352/),nM,6.2,167403,DB01577,Methamphetamine
,26159352,half-life,"We have thus successfully developed a novel multivalent METH-binding nanomedicine by conjugating multiple anti-METH scFvs to dendrimer nanoparticles, extending the scFv half-life from 1.3 (± 0.3) to 26 (± 2.6) hr.",A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26159352/),h,1.3,167404,DB01577,Methamphetamine
,26159352,half-life,"We have thus successfully developed a novel multivalent METH-binding nanomedicine by conjugating multiple anti-METH scFvs to dendrimer nanoparticles, extending the scFv half-life from 1.3 (± 0.3) to 26 (± 2.6) hr.",A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26159352/),h,26,167405,DB01577,Methamphetamine
,7120117,half-lives,The plasma pharmacokinetics of both PEA and NMPEA could be described by first-order kinetics which estimated half-lives of approximately 5 to 10 min.,Physiologic effects and plasma kinetics of beta-phenylethylamine and its N-methyl homolog in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7120117/),min,5 to 10,174110,DB01577,Methamphetamine
,24839971,equilibrium dissociation rate constant (KD),We hypothesized that treatment of pregnant rat dams with a dual reactive monoclonal antibody (mAb4G9) against (+)-methamphetamine [METH; equilibrium dissociation rate constant (KD) = 16 nM] and (+)-amphetamine (AMP; KD = 102 nM) could confer maternal and fetal protection from brain accumulation of both drugs of abuse.,Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839971/),nM,16,176519,DB01577,Methamphetamine
,24839971,KD,We hypothesized that treatment of pregnant rat dams with a dual reactive monoclonal antibody (mAb4G9) against (+)-methamphetamine [METH; equilibrium dissociation rate constant (KD) = 16 nM] and (+)-amphetamine (AMP; KD = 102 nM) could confer maternal and fetal protection from brain accumulation of both drugs of abuse.,Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24839971/),nM,102,176520,DB01577,Methamphetamine
,16123749,half-life,"We developed a computer-controlled intravenous methamphetamine (METH) administration procedure (dynamic infusion), which enables us to compensate for an important pharmacokinetic difference between rats and humans by imposing a 12-h half-life for the drug in rats.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h,12,177784,DB01577,Methamphetamine
,16123749,apparent half-life,"Dynamic infusion of 0.5 mg/kg METH produced a pharmacokinetic profile that closely simulates the METH exposure pattern in humans, including an apparent half-life of 11.6+/-1.3 h, and an area under the concentration vs time curve of 9.4 microM h, about 20-fold larger than results obtained with typical rat pharmacokinetics.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h,11.6,177785,DB01577,Methamphetamine
,16123749,area under the concentration vs time curve,"Dynamic infusion of 0.5 mg/kg METH produced a pharmacokinetic profile that closely simulates the METH exposure pattern in humans, including an apparent half-life of 11.6+/-1.3 h, and an area under the concentration vs time curve of 9.4 microM h, about 20-fold larger than results obtained with typical rat pharmacokinetics.",Human methamphetamine pharmacokinetics simulated in the rat: single daily intravenous administration reveals elements of sensitization and tolerance. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123749/),h·μM,9.4,177786,DB01577,Methamphetamine
over,18396472,recoveries,The recoveries were over 90% in all biological samples tested.,"Analysis of amphetamine-type stimulants and their metabolites in plasma, urine and bile by liquid chromatography with a strong cation-exchange column-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18396472/),%,90,178357,DB01577,Methamphetamine
,11862265,Trough levels,Trough levels of 3.3 and 6.0 ng / mL for L-amphetamine and L-methamphetamine suggest that steady state was achieved by the third dosing day for these metabolites.,"The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),[ng] / [ml],3.3,184467,DB01577,Methamphetamine
,11862265,Trough levels,Trough levels of 3.3 and 6.0 ng / mL for L-amphetamine and L-methamphetamine suggest that steady state was achieved by the third dosing day for these metabolites.,"The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),[ng] / [ml],6.0,184468,DB01577,Methamphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,8.6,184469,DB01577,Methamphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,9.5,184470,DB01577,Methamphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,1.5,184471,DB01577,Methamphetamine
,11862265,half-life,"The mean half-life of selegiline and N-desmethylselegiline of 8.6 and 9.5 h, respectively, was substantially longer than that obtained in single-dose experiments (1.5 and 3.8 h, respectively).","The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11862265/),h,3.8,184472,DB01577,Methamphetamine
,27798075,Peak plasma concentration (Cmax,Peak plasma concentration (Cmax = 122.6 ± 32.9 ng/mL) was reached at 1 hour (0.5-2 h) post-drug administration.,GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798075/),[ng] / [ml],122.6,187129,DB01577,Methamphetamine
,27798075,elimination half-life (t1/2,Mephedrone showed a rapid elimination half-life (t1/2 = 2.2 h) compared to other psychostimulants.,GC-MS Quantification Method for Mephedrone in Plasma and Urine: Application to Human Pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798075/),h,2.2,187130,DB01577,Methamphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],348.0,195990,DB01577,Methamphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],68,195991,DB01577,Methamphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,29.,195992,DB01577,Methamphetamine
,23395913,Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀),Area under the curve for concentration vs. time until 600 min from drug administration (AUC₀₋₆₀₀) increased from 348.0 to 689.8 μgmin/L for MDMA and from 29.9 to 243.4 μMmin for dopamine in response to co-administration of methamphetamine and MDMA compared to sole MDMA (12 mg/kg) administration.,"Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243,195993,DB01577,Methamphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],401.8,195994,DB01577,Methamphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),[μgmin] / [l],671.1,195995,DB01577,Methamphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,159.9,195996,DB01577,Methamphetamine
,23395913,AUC₀₋₆₀₀,"After sole methamphetamine or that with MDMA administration, AUC₀₋₆₀₀ of methamphetamine were 401.8 and 671.1 μgmin/L, and AUC₀₋₆₀₀ of dopamine were 159.9 and 243.4 μMmin.","Warning against co-administration of 3,4-methylenedioxymethamphetamine (MDMA) with methamphetamine from the perspective of pharmacokinetic and pharmacodynamic evaluations in rat brain. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23395913/),μMmin,243.4,195997,DB01577,Methamphetamine
,12394422,K(D),"Animals were trained to discriminate 5 or 10 mg/kg cocaine (rats), or 3 mg/kg (+)-amphetamine (pigeons) from saline, after which dose-response curves were determined for (+)-methamphetamine and other drugs before and after administration of a (+)-methamphetamine-specific monoclonal antibody (K(D) =250 nM).",Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394422/),nM,250,198525,DB01577,Methamphetamine
,23363010,T1/2,Pharmacokinetic studies found that the T1/2 of 4-MMC was about 1 hour in vivo in rat plasma and 90 minutes using in vitro liver microsomal assays.,Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363010/),h,1,201357,DB01577,Methamphetamine
,23363010,T1/2,Pharmacokinetic studies found that the T1/2 of 4-MMC was about 1 hour in vivo in rat plasma and 90 minutes using in vitro liver microsomal assays.,Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23363010/),min,90,201358,DB01577,Methamphetamine
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],6.5,204252,DB01577,Methamphetamine
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],14.7,204253,DB01577,Methamphetamine
,2515726,concentrations,"The mean concentrations of patients with Alzheimer's or Parkinson's disease were 6.5 +/- 2.5 ng/ml for A, 14.7 +/- 6.5 ng/ml for MA and 0.9 +/- 0.7 ng/ml for DES.",Pharmacokinetics and metabolism of selegiline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),[ng] / [ml],0.9,204254,DB01577,Methamphetamine
,2515726,recovery,"The metabolites of selegiline were excreted in urine, and the recovery as metabolites was 87%.",Pharmacokinetics and metabolism of selegiline. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2515726/),%,87,204255,DB01577,Methamphetamine
,9021435,elimination half-life,"As plasma levels of selegiline are very low and the elimination half-life is very short being about 9 minutes, therefore, a very sensitive and selective method for determining the 3 main metabolites desmethylselegiline (DMS), methamphetamine (MA) and amphetamine (A) was developed.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),min,9,206451,DB01577,Methamphetamine
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],5-6,206452,DB01577,Methamphetamine
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],6-7,206453,DB01577,Methamphetamine
,9021435,Cmax,"After application of a single oral dose of 5 mg selegiline the Cmax values of DMS reached 5-6 ng/ml, of MA 6-7 ng/ml and of A about 2 ng/ml.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [ml],2,206454,DB01577,Methamphetamine
,9021435,AUC infinity,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [h·ml],11,206455,DB01577,Methamphetamine
,9021435,MA,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[g] / [h·ml],130,206456,DB01577,Methamphetamine
,9021435,A,"The AUC infinity values were with DMS about 11 ng/ml x h +/- 4.5, with MA about 130 g/ml x h +/- 50 and with A about 50 ng/ml x h +/- 15.","Pharmacokinetics and bioequivalence of the main metabolites of selegiline: desmethylselegiline, methamphetamine and amphetamine after oral administration of selegiline. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9021435/),[ng] / [h·ml],50,206457,DB01577,Methamphetamine
,27206266,elimination half-life,The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA.,Human Pharmacology of Mephedrone in Comparison with MDMA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206266/),h,2.15,216678,DB01577,Methamphetamine
,27206266,elimination half-life,The elimination half-life for mephedrone was 2.15 h and 7.89 h for MDMA.,Human Pharmacology of Mephedrone in Comparison with MDMA. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27206266/),h,7.89,216679,DB01577,Methamphetamine
,28828691,half-life,Dihydro-mephedrone represented 10% of the amount of mephedrone in plasma and N-succinyl-nor-mephedrone was the metabolite eliminated with the longer half-life of 8.2 h.,Pharmacokinetics of Mephedrone and Its Metabolites in Human by LC-MS/MS. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828691/),h,8.2,222184,DB01577,Methamphetamine
,1362938,elimination half-life,The average elimination half-life was 10.1 hr (range of 6.4-15.1 hr).,Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1362938/),h,10.1,225169,DB01577,Methamphetamine
,19428944,maximum plasma concentration,"PMMA maximum plasma concentration of 4014+/-1122ng/mL was reached 30min after dosing, whereas the appearance of metabolites was rather delayed.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[ng] / [ml],4014,232878,DB01577,Methamphetamine
,19428944,half-life,"The disposition of PMMA was characterized by its approximate half-life of 1.0h, volume of distribution of 6.4L/kg and plasma clearance of 4.4L/h.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),h,1.0,232879,DB01577,Methamphetamine
,19428944,volume of distribution,"The disposition of PMMA was characterized by its approximate half-life of 1.0h, volume of distribution of 6.4L/kg and plasma clearance of 4.4L/h.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[l] / [kg],6.4,232880,DB01577,Methamphetamine
,19428944,plasma clearance,"The disposition of PMMA was characterized by its approximate half-life of 1.0h, volume of distribution of 6.4L/kg and plasma clearance of 4.4L/h.",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[l] / [h],4.4,232881,DB01577,Methamphetamine
,19428944,c(max),"PMMA tissue concentration exceeded plasma and the highest one was found in the lungs (c(max) 42,988+/-10,223ng/g).",Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),[ng] / [g],"42,988",232882,DB01577,Methamphetamine
,19428944,maximum brain/plasma ratio,The maximum brain/plasma ratio value of PMMA (15.8) and PMA (11.8) was reached after 8h of observation.,Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),,15.8,232883,DB01577,Methamphetamine
,19428944,maximum brain/plasma ratio,The maximum brain/plasma ratio value of PMMA (15.8) and PMA (11.8) was reached after 8h of observation.,Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19428944/),,11.8,232884,DB01577,Methamphetamine
,19800446,K(D),"These studies examined the in vivo pharmacokinetics and efficacy of five anti-methamphetamine monoclonal antibodies (mAbs, K(D) values from 11 to 250 nM) in rats.",Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800446/),nM,11 to 250,240971,DB01577,Methamphetamine
,19800446,t(1/2),"While no substantive differences in mAb systemic clearance (t(1/2)=6.1-6.9 days) were found, in vivo function was significantly reduced within 1-3 days for four of the five mAbs.",Functional and biological determinants affecting the duration of action and efficacy of anti-(+)-methamphetamine monoclonal antibodies in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800446/),d,6.1-6.9,240972,DB01577,Methamphetamine
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],90.7,258469,DB01577,Methamphetamine
,18065502,AUC,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ng] / [h·ml],57.4,258470,DB01577,Methamphetamine
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],4.6,258471,DB01577,Methamphetamine
,18065502,clearance,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),[ml] / [min],7.3,258472,DB01577,Methamphetamine
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,12.5,258473,DB01577,Methamphetamine
,18065502,elimination half-life,"In mice in vivo, selegiline increased AUC (90.7 +/- 5.8 versus 57.4 +/- 5.3 ng/h/ml, p < 0.05), decreased clearance (4.6 +/- 0.4 versus 7.3 +/- 0.3 ml/min, p < 0.05), and increased elimination half-life (12.5 +/- 6.3 versus 6.6 +/- 1.4 min, p < 0.05) of nicotine.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),min,6.6,258474,DB01577,Methamphetamine
,18065502,K(i),Selegiline preincubation increased inhibition in microsomes (3.7-fold) and CYP2A6 (14.8-fold); the K(i) for CYP2A6 was 4.2 muM.,Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,4.2,258475,DB01577,Methamphetamine
,18065502,K(i),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),muM,15.6,258476,DB01577,Methamphetamine
,18065502,k(inact),"Selegiline dose- and time-dependently inhibited nicotine metabolism by CYP2A6 (K(i) = 15.6 +/- 2.7 muM; k(inact) = 0.34 +/- 0.04 min(-1)), and the inhibition was irreversible in the presence of NADPH, indicating that it is a mechanism-based inhibitor of CYP2A6.",Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18065502/),1/[min],0.34,258477,DB01577,Methamphetamine
,24333768,plasma Cmax,Pharmacokinetic analysis revealed that a 24-hour intravenous infusion of methamphetamine at a dose of 0.500 mg/kg/h produced a plasma Cmax value of 25.9 ng/ml and a total exposure of 544 ng/ml over a 32 hour time frame.,Administration of low dose methamphetamine 12 h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333768/),[ng] / [ml],25.9,262714,DB01577,Methamphetamine
,24333768,total exposure,Pharmacokinetic analysis revealed that a 24-hour intravenous infusion of methamphetamine at a dose of 0.500 mg/kg/h produced a plasma Cmax value of 25.9 ng/ml and a total exposure of 544 ng/ml over a 32 hour time frame.,Administration of low dose methamphetamine 12 h after a severe traumatic brain injury prevents neurological dysfunction and cognitive impairment in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24333768/),[ng] / [ml],544,262715,DB01577,Methamphetamine
,16413604,elimination half-life,"The elimination half-life of methamphetamine was approximately 12 h, and selegiline did not alter clearance of methamphetamine.",A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16413604/),h,12,265657,DB01577,Methamphetamine
,9373724,ratio of formation-absorption rate constant,"Compartmental analysis indicates that the ratio of formation-absorption rate constant for the selegiline to N-desmethylselegiline pathway decreases from 1.57 +/- 1.04 for the first pulse to 0.61 +/- 0.54 for the second pulse of the pulsatile delivery system, suggesting that the upper portion of the GI tract has a greater capacity to convert selegiline to N-desmethylselegiline than the lower GI tract.",Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373724/),,1.57,269039,DB01577,Methamphetamine
,9373724,ratio of formation-absorption rate constant,"Compartmental analysis indicates that the ratio of formation-absorption rate constant for the selegiline to N-desmethylselegiline pathway decreases from 1.57 +/- 1.04 for the first pulse to 0.61 +/- 0.54 for the second pulse of the pulsatile delivery system, suggesting that the upper portion of the GI tract has a greater capacity to convert selegiline to N-desmethylselegiline than the lower GI tract.",Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9373724/),,0.61,269040,DB01577,Methamphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],"21,470",270748,DB01577,Methamphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],2229,270749,DB01577,Methamphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],"20,793",270750,DB01577,Methamphetamine
,19874650,C(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),[ng] / [ml],876,270751,DB01577,Methamphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,13.9,270752,DB01577,Methamphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,23.0,270753,DB01577,Methamphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,9.2,270754,DB01577,Methamphetamine
,19874650,T(max),"After 1.6 mg/kg, median C(max) were 21,470 (MDMA), 2229 (MDA), 20,793 (HMMA), and 876 ng/mL (HMA) at median T(max) of 13.9, 23.0, 9.2 and 23.3 h.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),h,23.3,270755,DB01577,Methamphetamine
,19874650,total urinary excretion,"In the first 24 h, 30.2-34.3% total urinary excretion occurred.","Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19874650/),%,30.2-34.3,270756,DB01577,Methamphetamine
